Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
39
Journal Issue
25
Pages
2791-2802
Date Issued
2021
Author(s)
Drilon A.
Duruisseaux M.
Han J.-Y.
Ito M.
Falcon C.
Yang S.-R.
Murciano-Goroff Y.R.
Chen H.
Okada M.
Molina M.A.
Wislez M.
Brun P.
Dupont C.
Branden E.
Rossi G.
Schrock A.
Ali S.
Gounant V.
Magne F.
Blum T.G.
Schram A.M.
Monnet I.
Sabari J.
Pérol M.
Zhu V.W.
Nagasaka M.
Doebele R.
Camidge D.R.
Arcila M.
Ou S.-H.I.
Moro-Sibilot D.
Rosell R.
Muscarella L.A.
Liu S.V.
Cadranel J.
Abstract
PURPOSE: Although NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion-positive lung cancer
SDGs
Other Subjects
antineoplastic agent; neu differentiation factor; NRG1 protein, human; oncoprotein; tumor marker; adult; aged; Asia; clinical trial; Europe; female; follow up; genetics; human; immunology; immunotherapy; lung tumor; male; middle aged; mortality; multicent
Publisher
NLM (Medline)
Type
journal article